Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor
- Author:
Min Kyu KANG
1
;
Heon Ju LEE
;
Joon Hyuk CHOI
Author Information
- Publication Type:Case Report
- From:Yeungnam University Journal of Medicine 2019;36(2):155-158
- CountryRepublic of Korea
- Language:English
- Abstract: Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare. Its features vary from subclinical elevation of serum aminotransferase to clinically apparent acute hepatitis, which is associated with immunologic reactions. Imatinib-induced hepatotoxicity with autoimmune-like features can be treated by the discontinuation of imatinib mesylate and the administration of oral steroids. Here, we report a case of late-onset imatinib-induced hepatitis with autoimmune-like features in a patient with metastatic GIST, which was improved by oral corticosteroids.
